Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04062448
Other study ID # CR108666
Secondary ID 54179060WAL2002
Status Completed
Phase Phase 2
First received
Last updated
Start date September 25, 2019
Est. completion date March 2, 2023

Study information

Verified date March 2024
Source Janssen Pharmaceutical K.K.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment naïve or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date March 2, 2023
Est. primary completion date August 24, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia (WM) in accordance with the consensus panel of the second International Workshop on Waldenstrom's Macroglobulinemia (IWWM) - Japanese participants with treatment naïve or relapsed/refractory WM - Measurable disease defined as serum monoclonal immunoglobulin M (IgM) greater than (>) 0.5 gram per deciliter (g/dL) - Symptomatic disease, requiring treatment - Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 2 - Hematology and biochemical values within protocol-defined limits - Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception while taking study drug. Women of childbearing potential must be practicing a highly effective, preferably user independent method of birth control during treatment with any drug in this study and for up to 12 months after the last dose of rituximab, 1 month after last dose of ibrutinib. Male participants must use an effective barrier method of contraception during the study and after receiving the last dose of ibrutinib, and for up to 12 months after last dose of rituximab if sexually active with a female of childbearing potential - Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol - Must be willing and able to adhere to the lifestyle restrictions specified in this protocol Exclusion Criteria: - Involvement of the central nervous system by WM - Prior exposure to ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors - Rituximab treatment within the last 12 months before the first dose of study intervention - Received any WM-related therapy <=30 days prior to first administration of study treatment - Plasmapheresis less than (<) 35 days prior to the initiation of study drug, except when at least one serum IgM central assessment was performed during the screening period and was >35 days from the most recent plasmapheresis procedure - History of other malignancies - Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug - Infection requiring systemic treatment that was completed <=14 days before the first dose of study drug - Currently active, clinically significant Child-Pugh Class B or C hepatic impairment - Inability or difficulty swallowing capsules, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function - Stroke or intracranial hemorrhage within 12 months prior to enrollment - Currently active, clinically significant cardiovascular disease - Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor - Infection with human immunodeficiency virus (HIV) or active infection with hepatitis B or hepatitis C virus - Major surgery within 4 weeks of first dose of study drug - Lactating or pregnant - Male participants who plan to father a child while enrolled in this study or within 3 months after the last dose of ibrutinib, and within 12 months after last dose of rituximab - Any contraindication to ibrutinib or rituximab including hypersensitivity to the active substance or to any of the excipients of ibrutinib or rituximab per local prescribing information - Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before the planned first dose of study intervention or is currently enrolled in an investigational study - Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg [for example], compromise the wellbeing) or that could prevent, limit, or confound the protocol-specified assessments - Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ibrutinib
Ibrutinib 420 mg will be administered orally.
Rituximab
Rituximab 375 mg/m^2 will be administered intravenously.

Locations

Country Name City State
Japan Kameda General Hospital Chiba
Japan National Cancer Center Hospital Chuo-Ku
Japan National Hospital Organization Kumamoto Medical Center Kumamoto City
Japan Matsuyama Red Cross Hospital Matsuyama-City
Japan Nagoya City University Hospital Nagoya-City
Japan Osaka Metropolitan University Hospital Osaka
Japan Osaka University Hospital Suita-City
Japan National Hospital Organization Disaster Medical Center Tachikawa
Japan University of Tsukuba Hospital Tsukuba-City

Sponsors (1)

Lead Sponsor Collaborator
Janssen Pharmaceutical K.K.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria ORR is defined as the percentage of participants achieving a best overall response of confirmed complete response (CR), very good partial response (VGPR) or partial response (PR) according to the modified sixth IWWM criteria (National Comprehensive Cancer Network [NCCN] version 2, 2019), as assessed by the Independent Review Committee (IRC). CR: Immunoglobulin M (IgM) in normal range, disappearance of monoclonal protein by immunofixation, no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (if present at baseline) along with no signs or symptoms attributable to Waldenstrom's Macroglobulinemia (WM); VGPR and PR: greater than or equal to (>=) 90 percent (%) (for VGPR) and >=50% (for PR) reduction of serum IgM, decrease in adenopathy/organomegaly (if present at baseline) on physical examination or computerized tomography (CT) scan, no new symptoms or signs of active disease. Up to 1 year 11 months
Secondary Progression Free Survival (PFS) Assessed by Independent Review Committee PFS was defined as duration from the date of initial dose of ibrutinib to the date of first documented evidence of disease progression or death, whichever occurred first regardless of the use of subsequent antineoplastic therapy prior to documented disease progression or death. Kaplan-Meier method was used for the analysis. From the date of initial dose up to 3 years and 5 months
Secondary Plasma Concentrations of Ibrutinib Plasma concentrations of ibrutinib were reported. Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
Secondary Plasma Concentrations of Metabolite PCI-45227 Plasma concentrations of metabolite PCI-45227 were reported. Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
Secondary Number of Participants With Myeloid Differentiation Primary Response Gene 88 (MYD88) Biomarker Mutation Number of participants with MYD88 biomarker mutations were reported. MYD88 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study. Day 1 of Week 1
Secondary Number of Participants With C-X-C Chemokine Receptor Type 4 (CXCR-4) Biomarker Mutations Number of participants with CXCR-4 biomarker mutations were reported. CXCR-4 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study. Day 1 of Week 1
Secondary Number of Participants With Treatment- Emergent Adverse Events (TEAEs) An adverse event was defined as any untoward medical event that occurred in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs were defined as any AE that occurred at or after the initial administration of study intervention through the day of last dose plus 30 days. From first dose of study drug up to 30 days post last dose of study drug (that is, up to 40.6 months)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT03630042 - Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Recruiting NCT05952037 - Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia Phase 2
Completed NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Recruiting NCT03679455 - A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 Phase 2
Not yet recruiting NCT05099471 - Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia Phase 2
Not yet recruiting NCT04830046 - Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Active, not recruiting NCT03620903 - Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia Phase 2
Not yet recruiting NCT04702932 - Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Completed NCT00777738 - Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia Phase 2
Completed NCT00608361 - Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Phase 1
Completed NCT00438880 - Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT00075478 - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase 3
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Recruiting NCT04116437 - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Phase 2